U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07540832) titled 'Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC' on April 14.
Brief Summary: This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Hepatocellular Carcinoma (HCC)
Intervention:
DRUG: WGI-0301
WGI-0301 at Maximum Tolerated Dose (MTD)
DRUG: WGI-0301
WGI-0301 at ...